← Back to Search

Antidepressant

Trazodone for Early Alzheimer's Disease (REST Trial)

Verified Trial
Phase 2
Recruiting
Led By Barry Greenberg, PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Do you have memory concerns or sleep problems?
Do you have someone who could accompany you to the study visits?
Must not have
You have been diagnosed with Sleep Apnea
Are you currently taking any sleep medications that you're not willing or able to stop for two weeks prior to the study?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and end of study, up to 12 weeks

Summary

This trial will investigate whether trazodone can improve sleep and memory by looking at hippocampal excitability.

Who is the study for?
This trial is for adults with mild cognitive impairment, memory problems, and sleep complaints. They must be in good health, able to undergo MRI scans, and have a caregiver who can provide information. Excluded are those under 55, with severe sleep apnea or dementia, allergic to trazodone, using sleep meds or substances, having major psychiatric episodes or unstable medical conditions.
What is being tested?
The study tests if Trazodone improves sleep and memory in early Alzheimer's by increasing total sleep time and Slow Wave Sleep (SWS). Participants will either receive Trazodone or a placebo without knowing which one they're taking.
What are the potential side effects?
Trazodone may cause drowsiness, dizziness upon standing up too fast (orthostatic hypotension), dry mouth, blurred vision or confusion. It might also affect heart rhythm (QTc prolongation) especially at higher doses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and end of study, up to 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and end of study, up to 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in SWS intensity between the treatment arms
Change in Slow Wave Sleep (SWS) duration between the treatment arms
Change in self reported sleep measure Epworth Sleepiness Score (ESS) between treatment arms
+4 more
Secondary study objectives
Change in hippocampal activation on Function Magnetic Resonance Imaging (fMRI) measures during memory functioning between treatment arms
Change in memory performance between treatment arms

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Trazodone FirstActive Control2 Interventions
Trazodone (50 mg at bedtime) and then placebo after a 4-week washout period.
Group II: Placebo FirstPlacebo Group2 Interventions
Placebo and then Trazodone (50 mg at bedtime) after a 4-week washout period.

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,326 Previous Clinical Trials
14,874,629 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,788 Previous Clinical Trials
28,184,413 Total Patients Enrolled
Barry Greenberg, PhDPrincipal InvestigatorJohns Hopkins University

Media Library

Trazodone (Antidepressant) Clinical Trial Eligibility Overview. Trial Name: NCT05282550 — Phase 2
Sleep Disorder Research Study Groups: Trazodone First, Placebo First
Sleep Disorder Clinical Trial 2023: Trazodone Highlights & Side Effects. Trial Name: NCT05282550 — Phase 2
Trazodone (Antidepressant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05282550 — Phase 2
Sleep Disorder Patient Testimony for trial: Trial Name: NCT05282550 — Phase 2
~55 spots leftby Mar 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top